ANAPTYSBIO INC (ANAB) Forecast, Price Target & Analyst Ratings
NASDAQ:ANAB • US0327241065
64.7234 USD
+2.71 (+4.38%)
Last: Mar 11, 2026, 01:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ANAPTYSBIO INC (ANAB).
Forecast Snapshot
Consensus Price Target
$65.87
+ 1.78% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.82
Revenue Estimate28.015M
ChartMill Buy Consensus
85.26%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$65.87
Upside
+ 1.78%
From current price of $64.72 to mean target of $65.87, Based on 19 analyst forecasts
Low
$36.36
Median
$66.81
High
$105.00
Price Target Revisions
1 Month
0.00%
3 Months
7.19%
Price Target Summary
19 Wall Street analysts provided a forecast for the next 12 months for ANAB. The average price target is 65.88 USD. This implies a price increase of 1.78% is expected in the next year compared to the current price of 64.7234.
The average price target has been revised upward by 7.19% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.26%
ANAB was analyzed by 19 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ANAB.
In the previous month the buy percentage consensus was at a similar level.
ANAB was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Truist Securities | Maintains | Hold -> Hold |
| 2026-03-05 | Stifel | Maintains | Buy -> Buy |
| 2026-03-04 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-20 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-11-24 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-10 | Truist Securities | Maintains | Hold -> Hold |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-29 | Stifel | Maintains | Buy -> Buy |
| 2025-10-15 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-09-30 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-09-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-12 | UBS | Maintains | Neutral -> Neutral |
| 2025-08-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-07-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-06-04 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-05-28 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-06 | Guggenheim | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.82
Revenue Estimate28.015M
Revenue Q2Q0.88%
EPS Q2Q36.21%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.81%
EPS (1 Month)
1.97%
EPS (3 Months)
-0.45%
Next Earnings Summary
ANAB is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.82 USD and the consensus revenue estimate is 28.02M USD.
The next earnings revenue estimate has been revised downward by 0.81% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.29M -83.71% | 17.157M 66.73% | 91.28M 432.03% | 214.97M 135.51% | 127.21M -40.82% | 181.96M 43.04% | 292.38M 60.68% | 326.32M 11.61% | 499.22M 52.98% | 709.19M 42.06% | 881.18M 24.25% | 1.129B 28.12% | |
| EBITDA YoY % growth | -114.47M -103.72% | -156.42M -36.65% | -114.343M 26.90% | 5.834M 105.10% | -5.355M -191.79% | 20.227M 477.72% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -115.15M -102.69% | -157.072M -36.41% | -114.949M 26.82% | 23.143M 120.13% | -103.894M -548.92% | -169.789M -63.43% | -135.404M 20.25% | -77.496M 42.77% | 103.17M 233.13% | 350.37M 239.60% | 507.24M 44.77% | 785.73M 54.90% | |
| Operating Margin | -1,119.05% | -915.50% | -125.93% | 10.77% | -81.67% | -93.31% | -46.31% | -23.75% | 20.67% | 49.40% | 57.56% | 69.60% | |
| EPS YoY % growth | -4.57 -122.93% | -6.08 -33.04% | -5.21 14.31% | -1.28 90.02% | -4.67 -797.23% | -5.50 -17.85% | -3.18 42.07% | -1.83 42.67% | 3.86 311.17% | 7.69 99.47% | 10.89 41.64% | 15.24 39.89% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.82 36.21% | -1.01 24.77% | -1.21 -333.44% | -0.99 -162.70% | -0.38 53.28% | -0.41 59.63% | -0.44 64.12% | -0.47 52.85% |
| Revenue Q2Q % growth | 28.015M 0.88% | 29.356M 31.86% | 31.394M -58.87% | 37.788M -65.09% | 22.708M -18.94% | 22.708M -22.65% | 22.708M -27.67% | 22.708M -39.91% |
| EBITDA Q2Q % growth | -18.044M 34.13% | -11.342M 56.18% | -10.067M -128.66% | 55.712M 150.38% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.532M 21.81% | -19.995M 23.59% | -24.509M -170.62% | -30.226M -167.71% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-82.96%
EPS Next 5 Year
56.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
10.80%
Revenue Next 5 Year
18.35%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
28.67%
EBIT Next 5 Year
N/A
ANAPTYSBIO INC / ANAB Forecast FAQ
What is the price target for ANAB stock?
19 analysts have analysed ANAB and the average price target is 65.88 USD. This implies a price increase of 1.78% is expected in the next year compared to the current price of 64.7234.
Can you provide the upcoming earnings date for ANAPTYSBIO INC?
ANAPTYSBIO INC (ANAB) will report earnings on 2026-05-04, after the market close.
What are the consensus estimates for ANAB stock next earnings?
The consensus EPS estimate for the next earnings of ANAPTYSBIO INC (ANAB) is -0.82 USD and the consensus revenue estimate is 28.02M USD.
Can you provide the analyst count for ANAPTYSBIO INC stock?
The number of analysts covering ANAPTYSBIO INC (ANAB) is 19.